Novogenia AG
Novogenia AG is the stock-listed parent company of Novogenia GmbH.
PERSONALIZED products, services and therapies based on YOUR unique BIOLOGICAL DATA
Novogenia AG harnesses advances in biotechnology and artificial intelligence to create highly personalized solutions from scientific lab-analysis data — spanning genetic testing, personalized supplements and cosmetics, and advanced therapies (personalized infusion therapies and IVF / reproductive genetics). The Group is the listed holding company (ISIN DE000A3C35W0), traded on XETRA and the Munich Stock Exchange.
New headquarters & laboratory
Our mission
Analyse. Learn. Solve. Explore. — the principle behind every Novogenia product.
Analyse
Using advanced technologies in our laboratories to decypher the human genome and metabolome.
- Genetic analysis for optimized nutrition
- Disease prevention & therapy optimization
- Virological & diagnostic analyses
- Genetic analysis for IVF improvement
Learn
Using artificial intelligence to interpret genetic data for unparalleled insights into the body.
- AI-powered identification of genetic traits
- Detect inefficiencies in therapies via lab analytics
- “Analyse → product → re-analyse” feedback loop
- Decypher millions of scientific publications
Solve
Based on unique personal data, personalized solutions are produced for each individual.
- Genetic reports with personalized action plans
- Personalized supplements & cosmetics
- Optimized therapies and IVF cycles
- Personalized drug development as infusions
Explore
Applying the principle of Analyse · Learn · Solve across healthcare and biotechnology.
- Acquisitions in the healthcare and biotech sector
- In-house startups to expand the portfolio
- Clinical studies to assess product performance
Our companies
The operating companies and strategic investments organised under Novogenia AG.
Novogenia GmbH100%
NovoMedic GmbH70%
305Care GmbH85%
HLN Genetik GmbH85%
Mendelio Srl70%
Medicopharm AG100%
INOPHA GmbH51%
ChiruTec GmbH51%
REVIV
Spot Health Inc.
GenomeLink
Nephrogen Inc.Business segments & companies
All brands & companies →Three operating divisions — Diagnostics & Personalized Products (€52M cash reserves), Drug Import & Medical Devices, and Minority Investments (€10.6M invested) — plus the Group’s full company org chart and revenue-by-segment charts.
Explore the full Group structure & segments →
Company achievements
A fully integrated value chain — everything from laboratory to finished product, in house.
Our global market
A globally active group — with resellers and customers across the world.
New building & expansion
A €35 million investment in the next decade of capacity.
New building & capacity expansion
Novogenia is investing €35 million in a new, state-of-the-art headquarters and laboratory complex — massively expanding diagnostic, supplement and cosmetics production capacity to meet accelerating global demand. The Group expects to move into the new building at the end of 2027.
- Expanded high-throughput genetic laboratory
- Scaled in-house supplement & cosmetics manufacturing
- Automation and additional clean-room capacity
- Room for the next decade of growth
Inside Novogenia
Tour through the Novogenia Facility
Step inside our Salzburg headquarters — the accredited high-throughput genetic and blood laboratory, the in-house supplement and cosmetics manufacturing, and the teams that run the full value chain from sample to finished product.
Media
Films from the Novogenia Academy — the science behind our analyses and products.
Get Certified
NOVO Academy is the group’s online education platform — structured courses, expert talks and certifications on human genetics, personalized nutrition and cosmetics, and how to put DNA-based analysis to work in everyday practice. Built for partners, health professionals and curious customers alike.
- Genetics & personalized-health fundamentals
- Certified courses for partners & professionals
- Expert talks and continuously updated science
The Novogenia Stock
Share details →Live price development on XETRA / Munich, with the key facts of the Novogenia AG share.
Analyst price targets
What independent analysts say about the Novogenia AG share — each broker’s rating, 12-month price target and full research note.
Third-party analyst opinions (ODDO BHF and GBC Research), reproduced for information only — not investment advice or a recommendation by Novogenia AG.
Dividends
Share details →Novogenia AG follows a dividend strategy: as long as the development of the company is not impeded, it aims to pay a dividend to its shareholders every year.
Total payout = dividend per share × 12,000,000 shares outstanding. The 2025 dividend is subject to approval by the Annual General Meeting.
Our brands
All brands & companies →Consumer brands built on the Group’s genetic-science platform.
Genopedia
An accessible knowledge platform that translates the latest genetic science into clear, actionable insights — Novogenia’s encyclopedia of human genetics, connecting every analysis to the research behind it.
Personalized daily supplementsNovoDaily
A personalized daily-supplement subscription: each sachet is formulated from the customer’s own genetic and lifestyle data and produced in-house — the right nutrients, in the right dose, every day.
Leadership
The people leading Novogenia AG.
Dr. Daniel Wallerstorfer PhD, BSc
Molecular biologist with a PhD in Biotechnology and founder of Novogenia. Daniel built the company into a leading laboratory for genetic testing and personalized health, driving the Group’s research, technology and product innovation. During the COVID-19 pandemic the group became a leading SARS-CoV-2 testing laboratory, and the holding company was listed on the Munich Stock Exchange. He is also a science author who educates the public about the power of our genes.
Management Board
Felix Bausch
Member of the Management Board, leading Investor Relations and Mergers & Acquisitions for the Group from Munich — managing the capital-market relationships and the acquisition pipeline that drive Novogenia’s growth strategy.
Matthias Probst Mag. (FH)
Co-founder of Novogenia GmbH and Chief Financial Officer of the Group. Matthias oversees finance across the holding and its operating companies, providing the financial foundation for the Group’s expansion.
Supervisory Board
Christian Dreyer Dipl.-Ing., MBA
Chairman of the Supervisory Board, bringing capital-market and governance experience to the oversight of Novogenia AG and the long-term interests of its shareholders.
Florian Renner
Vice Chairman of the Supervisory Board, supporting the governance and strategic oversight of Novogenia AG alongside the Chairman and contributing capital-market expertise.
Caroline Probst
Member of the Supervisory Board, contributing expertise in finance and controlling to the board’s oversight of the Group’s financial management and reporting.
Investor Relations at a glance
Everything for shareholders and the capital market — organised across three areas.
The Share & Research
News, Reports & Calendar
Investor & press contact
Questions from shareholders, analysts or media? Our Investor Relations team is happy to help.